{
    "doi": "https://doi.org/10.1182/blood.V120.21.3022.3022",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=2382",
    "start_url_page_num": 2382,
    "is_scraped": "1",
    "article_title": "Hematogones Contained in CD34+ Apheresis Products for Hematopoietic Progenitor Cell Transplantation Have No Adverse Impact On Engraftment Outcomes. ",
    "article_date": "November 16, 2012",
    "session_type": "711. Cell Collection and Processing: Poster II",
    "topics": [
        "apheresis",
        "engraftment",
        "hematopoietic stem cell transplantation",
        "tissue transplants",
        "transplantation",
        "adverse effects",
        "flow cytometry",
        "immunophenotyping",
        "prognostic factors",
        "absolute neutrophil count"
    ],
    "author_names": [
        "Sarah L. Ondrejka, DO",
        "Eric D. Hsi, MD",
        "Lisa A. Rybicki, MS",
        "Deborah A. Katanik",
        "Brian J. Bolwell, MD",
        "Hien K. Duong, MD"
    ],
    "author_affiliations": [
        [
            "Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA, "
        ],
        [
            "Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA, "
        ],
        [
            "Quantitative Health Sciences, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA, "
        ],
        [
            "Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA, "
        ],
        [
            "Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA, "
        ],
        [
            "Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA"
        ]
    ],
    "first_author_latitude": "41.500755000000005",
    "first_author_longitude": "-81.61845635",
    "abstract_text": "Abstract 3022 Flow cytometric enumeration of CD34+ stem cells is a critical step in evaluation of graft adequacy prior to harvest for hematopoietic progenitor stem cell transplantation (HPSCT). The International Society of Hematotherapy and Graft Engineering (ISHAGE) established a standardized protocol in 1996 that is widely used for this purpose. Use of the sequential gating strategy routinely identifies a separate population of CD34+ events, with low side scatter and immunophenotype characteristic of hematogones (B-lymphocyte precursors) that are not excluded from the total CD34% according to the guideline. Whether including hematogones, presumably committed to lymphoid development, impacts engraftment is unknown. We investigated the effect of hematogones on engraftment. Apheresis samples for CD34+ stem cell enumeration were analyzed for the presence (\u22650.01%) of the additional CD34+ population by flow cytometry prospectively for 12 months. Patients who underwent HPSCT in that time frame were categorized according to whether their infused product(s) contained hematogones (negative= 500 K/\u03bcL) and platelet (PLT) engraftment (days to platelet count >20 K/\u03bcL). In a 12 month review of 274 apheresis samples, 61% harbored hematogones, comprising a median of 7.1% of total CD34+ cells (range 1.3 \u2013 78.0). Patients (n=147, Table 1 ) received stem cell infusions that were negative, mixed, or positive for hematogones. The positive group had hematogones ranging from 0.22 \u2013 6.31% of total CD34+ cells; hematogone % in the mixed group could not be quantitated. On multivariable analysis, patients in the mixed and positive groups had a marginally greater likelihood of neutrophil engraftment than those with negative hematogones ( Table 2 ). Hematogones had no impact on platelet engraftment. Hematogones are frequently included in the ISHAGE gating protocol. Reporting CD34% values that are inclusive of hematogones does not have an adverse effect on engraftment. Preliminary analysis suggests that receiving graft products that contain hematogones may predict for better neutrophil engraftment. Whether this is a direct or indirect effect of hematogones in the sample is unknown. Table 1. Descriptive Data by Hematogone Group (n=60, n=24, n=63)  . Negative # (range) % . Mixed # (range) % . Positive # (range) % . Median age at transplant, years 58 (27\u201376) 54 (38\u201369) 54 (15\u201376) Male 40 66.7 16 66.7 34 54.0 Diagnosis type 48 80.0 23 95.8 39 61.9 Lymphoid    Transplant type 47 78.3 23 95.8 27 42.9 Autologous (Auto) 4 6.7 \u2013 31 49.2 Myeloablative allogeneic (MA) 5 8.3 1 4.2 2 3.2 Reduced intensity allogeneic (RIC) 4 6.7 \u2013 3 4.8 Mini allogeneic (Mini)    Cell source 55 91.7 24 100.0 36 57.1 Peripheral stem cells (PSC) 1 1.7 \u2013 24 38.1 Bone marrow (BM) 4 6.7 \u2013 3 4.8 Umbilical cord (UC)    Median CD34+ dose, \u00d7 10 6 /kg 5.06 (0.01\u201327.60) 4.38 (1.81\u20138.59) 4.00 (0.02\u201311.91) Total nucleated cell dose (TNC), \u00d7 10 8 /kg 9.00 (0.27\u201346.88) 18.20 (8.55\u201337.13) 4.54 (0.27\u201324.93) . Negative # (range) % . Mixed # (range) % . Positive # (range) % . Median age at transplant, years 58 (27\u201376) 54 (38\u201369) 54 (15\u201376) Male 40 66.7 16 66.7 34 54.0 Diagnosis type 48 80.0 23 95.8 39 61.9 Lymphoid    Transplant type 47 78.3 23 95.8 27 42.9 Autologous (Auto) 4 6.7 \u2013 31 49.2 Myeloablative allogeneic (MA) 5 8.3 1 4.2 2 3.2 Reduced intensity allogeneic (RIC) 4 6.7 \u2013 3 4.8 Mini allogeneic (Mini)    Cell source 55 91.7 24 100.0 36 57.1 Peripheral stem cells (PSC) 1 1.7 \u2013 24 38.1 Bone marrow (BM) 4 6.7 \u2013 3 4.8 Umbilical cord (UC)    Median CD34+ dose, \u00d7 10 6 /kg 5.06 (0.01\u201327.60) 4.38 (1.81\u20138.59) 4.00 (0.02\u201311.91) Total nucleated cell dose (TNC), \u00d7 10 8 /kg 9.00 (0.27\u201346.88) 18.20 (8.55\u201337.13) 4.54 (0.27\u201324.93) View Large Table 2. Predictors for Neutrophil Engraftment  . Univariable HR 95% CI P-value . Multivariable HR 95% CI P-value . Hematogones   Mixed/Negative 1.8 1.1\u20132.9 0.022 1.9 1.2\u20133.2 0.012 Positive/Negative 0.6 0.4\u20130.9 0.012 1.5 0.9\u20132.2 0.09 Age   Per 10 year increase 1.2 1.0\u20131.4 0.024  Diagnosis type   Lymphoid/others 2.1 1.4\u20133.2 <0.001  Transplant type   MA/Auto 0.1 0.1\u20130.2 <0.001 0.1 0.1\u20130.2 <0.001 Mini+RIC/Auto 0.3 0.1\u20130.5 <0.001 0.3 0.1\u20130.5 <0.001 Cell source   BM/PSC 0.2 0.1\u20130.3 <0.001  UC/PSC 0.1 0.1\u20130.3 <0.001  CD34+ dose, \u00d7 10 6 /kg   Per 1 \u00d7 10 6 /kg increase 1.98 1.61\u20132.43 <0.001 1.77 1.38\u20132.26 <0.001 TNC, \u00d7 10 8 /kg   Per 1 \u00d7 10 8 /kg increase 1.33 1.21\u20131.47 <0.001  . Univariable HR 95% CI P-value . Multivariable HR 95% CI P-value . Hematogones   Mixed/Negative 1.8 1.1\u20132.9 0.022 1.9 1.2\u20133.2 0.012 Positive/Negative 0.6 0.4\u20130.9 0.012 1.5 0.9\u20132.2 0.09 Age   Per 10 year increase 1.2 1.0\u20131.4 0.024  Diagnosis type   Lymphoid/others 2.1 1.4\u20133.2 <0.001  Transplant type   MA/Auto 0.1 0.1\u20130.2 <0.001 0.1 0.1\u20130.2 <0.001 Mini+RIC/Auto 0.3 0.1\u20130.5 <0.001 0.3 0.1\u20130.5 <0.001 Cell source   BM/PSC 0.2 0.1\u20130.3 <0.001  UC/PSC 0.1 0.1\u20130.3 <0.001  CD34+ dose, \u00d7 10 6 /kg   Per 1 \u00d7 10 6 /kg increase 1.98 1.61\u20132.43 <0.001 1.77 1.38\u20132.26 <0.001 TNC, \u00d7 10 8 /kg   Per 1 \u00d7 10 8 /kg increase 1.33 1.21\u20131.47 <0.001  View Large Disclosures: No relevant conflicts of interest to declare."
}